X4 Pharmaceuticals Inc (XFOR)

$4.21 -0.09 (-2.09%)
Market Cap 426.33M
Revenue (ttm) 35.11M
Net Income (ttm) -79.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -225.58%
Debt to Equity Ratio 0.49
Volume 362,000
Avg Vol 841,260
Day's Range N/A - N/A
Shares Out 99.15M
Stochastic %K 21%
Beta 0.37
Analysts Strong Sell
Price Target $11.60

Company Profile

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufac...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 529 8300
Address:
61 North Beacon Street, 4th Floor, Boston, United States
starkist
starkist Aug. 14 at 11:44 AM
$XFOR something is going on here ...whatever it is ...i haven't a clue.. been sitting on this for too many years.. and only once in very blue moon do i come here and take a peak.. but i like this hint of northern movement.
1 · Reply
Pope25
Pope25 Aug. 10 at 8:05 PM
$XFOR ok boys, time to load up
0 · Reply
TwongStocks
TwongStocks Aug. 6 at 8:33 PM
$XFOR 10-Q filed https://www.sec.gov/ix?doc=/Archives/edgar/data/1501697/000150169726000068/xfor-20260630.htm • 99,146,743 shares outstanding as of July 31 • $2.4M in product revenue. $6.4M in license revenue from Norgine, which included $5.5M in milestone payments. Total revenue $8.8M. • Net loss per share ($0.13)
2 · Reply
Jeff226
Jeff226 Aug. 5 at 2:56 PM
$XFOR
0 · Reply
StockScanners
StockScanners Jul. 11 at 10:37 PM
$XFOR keep watch if this holds above 4.24
0 · Reply
IN0V8
IN0V8 Jul. 10 at 3:24 PM
$XFOR Buy Wells Fargo initiates coverage with overweight rating Wells Fargo initiates target price $11
0 · Reply
dl42
dl42 Jul. 10 at 11:55 AM
$XFOR here some positive news
0 · Reply
Jeff226
Jeff226 Jun. 30 at 6:17 PM
$XFOR
0 · Reply
Pope25
Pope25 Jun. 26 at 2:49 AM
$XFOR might go visit the low 3’s again
0 · Reply
Skusek
Skusek May. 31 at 11:29 PM
$XFOR Still heavily unprofitable: X4 reported a 2025 net loss of about $79 million and continues to post significant quarterly losses despite restructuring efforts.•.
1 · Reply
Latest News on XFOR
X4 Pharmaceuticals reports Q2 EPS (13c), consensus (18c)

2026-08-06T21:40:20.000Z - 12 days ago

X4 Pharmaceuticals reports Q2 EPS (13c), consensus (18c)

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Aug 6, 2026, 4:15 PM EDT - 12 days ago

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Quarterly report: Q2 2026

Aug 6, 2026, 7:00 AM EDT - 13 days ago

X4 Pharmaceuticals Quarterly report: Q2 2026

X4 Pharmaceuticals Earnings release: Q2 2026

Aug 6, 2026, 7:00 AM EDT - 13 days ago

X4 Pharmaceuticals Earnings release: Q2 2026

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 3, 2026, 4:30 PM EDT - 15 days ago

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals initiated with an Overweight at Wells Fargo

2026-07-10T10:25:42.000Z - 5 weeks ago

X4 Pharmaceuticals initiated with an Overweight at Wells Fargo

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 7, 2026, 4:30 PM EDT - 6 weeks ago

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals appoints CAMP4 Therapeutics CFO Kelly Gold to board

2026-07-01T11:20:53.000Z - 7 weeks ago

X4 Pharmaceuticals appoints CAMP4 Therapeutics CFO Kelly Gold to board

CAMP

X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors

Jul 1, 2026, 7:00 AM EDT - 7 weeks ago

X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors

X4 Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 12:50 PM EDT - 2 months ago

X4 Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

X4 Pharmaceuticals initiated with an Outperform at Leerink

2026-06-02T10:35:48.000Z - 2 months ago

X4 Pharmaceuticals initiated with an Outperform at Leerink

X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

May 27, 2026, 7:00 AM EDT - 3 months ago

X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

X4 Pharmaceuticals reports Q1 EPS (16c), consensus (20c)

2026-05-07T06:33:22.000Z - 3 months ago

X4 Pharmaceuticals reports Q1 EPS (16c), consensus (20c)

X4 Pharmaceuticals files $300M mixed securities shelf

2026-05-07T01:47:41.000Z - 3 months ago

X4 Pharmaceuticals files $300M mixed securities shelf

X4 Pharmaceuticals Registration statement: Registration filing

May 6, 2026, 8:00 AM EDT - 3 months ago

X4 Pharmaceuticals Registration statement: Registration filing

X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 6, 2026, 7:15 AM EDT - 3 months ago

X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Quarterly report: Q1 2026

May 6, 2026, 7:00 AM EDT - 3 months ago

X4 Pharmaceuticals Quarterly report: Q1 2026

X4 Pharmaceuticals Earnings release: Q1 2026

May 6, 2026, 7:00 AM EDT - 3 months ago

X4 Pharmaceuticals Earnings release: Q1 2026

X4 Pharmaceuticals announces EC approval of Xolremdi

2026-04-29T16:37:43.000Z - 4 months ago

X4 Pharmaceuticals announces EC approval of Xolremdi

X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union

Apr 29, 2026, 7:00 AM EDT - 4 months ago

X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union

X4 Pharmaceuticals Proxy statement: Proxy filing

Mar 20, 2026, 8:00 AM EDT - 5 months ago

X4 Pharmaceuticals Proxy statement: Proxy filing

X4 Pharmaceuticals Proxy statement: Proxy filing

Mar 20, 2026, 8:00 AM EDT - 5 months ago

X4 Pharmaceuticals Proxy statement: Proxy filing

X4 Pharmaceuticals reports Q4 EPS (22c), consensus (35c)

2026-03-17T11:20:56.000Z - 5 months ago

X4 Pharmaceuticals reports Q4 EPS (22c), consensus (35c)

X4 Pharmaceuticals sees cash runway through 2028

2026-03-17T11:20:44.000Z - 5 months ago

X4 Pharmaceuticals sees cash runway through 2028

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 17, 2026, 7:15 AM EDT - 5 months ago

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Earnings release: Q4 2025

Mar 17, 2026, 7:00 AM EDT - 5 months ago

X4 Pharmaceuticals Earnings release: Q4 2025

X4 Pharmaceuticals Annual report: Q4 2025

Mar 17, 2026, 7:00 AM EDT - 5 months ago

X4 Pharmaceuticals Annual report: Q4 2025

X4 Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Mar 11, 2026, 10:00 AM EDT - 5 months ago

X4 Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

X4 Pharmaceuticals initiated with a Buy at Guggenheim

2026-03-09T10:51:50.000Z - 5 months ago

X4 Pharmaceuticals initiated with a Buy at Guggenheim

X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference

Mar 4, 2026, 7:00 AM EST - 6 months ago

X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference

X4 Pharmaceuticals receives positive CHMP opinion for mavorixafor

2026-02-27T12:07:32.000Z - 6 months ago

X4 Pharmaceuticals receives positive CHMP opinion for mavorixafor

X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome

Feb 27, 2026, 7:00 AM EST - 6 months ago

X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome

X4 Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 12, 2026, 12:30 PM EST - 6 months ago

X4 Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

X4 Pharmaceuticals Slides: Corporate presentation

Feb 10, 2026, 6:00 AM EST - 6 months ago

X4 Pharmaceuticals Slides: Corporate presentation

X4 Pharmaceuticals to Participate in Guggenheim's Emerging Outlook: Biotech Summit 2026

Feb 3, 2026, 7:00 AM EST - 7 months ago

X4 Pharmaceuticals to Participate in Guggenheim's Emerging Outlook: Biotech Summit 2026

X4 Pharmaceuticals price target raised to $10 from $7.50 at Stifel

2025-12-05T11:40:18.000Z - 9 months ago

X4 Pharmaceuticals price target raised to $10 from $7.50 at Stifel

X4 Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 8:30 AM EST - 10 months ago

X4 Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

X4 Pharmaceuticals price target raised to $5 from $3.50 at H.C. Wainwright

2025-11-10T11:25:30.000Z - 10 months ago

X4 Pharmaceuticals price target raised to $5 from $3.50 at H.C. Wainwright

X4 Pharmaceuticals to Participate in Guggenheim's Second Annual Healthcare Innovation Conference

Nov 5, 2025, 4:01 PM EST - 10 months ago

X4 Pharmaceuticals to Participate in Guggenheim's Second Annual Healthcare Innovation Conference

X4 Pharmaceuticals price target lowered to $7.50 from $9 at Stifel

2025-11-05T17:20:16.000Z - 10 months ago

X4 Pharmaceuticals price target lowered to $7.50 from $9 at Stifel

X4 Pharmaceuticals Quarterly report: Q3 2025

Nov 5, 2025, 8:00 AM EST - 10 months ago

X4 Pharmaceuticals Quarterly report: Q3 2025

X4 Pharmaceuticals Earnings release: Q3 2025

Nov 5, 2025, 8:00 AM EST - 10 months ago

X4 Pharmaceuticals Earnings release: Q3 2025

X4 Pharmaceuticals reports Q3 EPS (69c), consensus (84c)

2025-11-05T12:05:28.000Z - 10 months ago

X4 Pharmaceuticals reports Q3 EPS (69c), consensus (84c)

X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 5, 2025, 7:00 AM EST - 10 months ago

X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million

Oct 27, 2025, 7:05 PM EDT - 10 months ago

X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million

X4 Pharmaceuticals 45.87M share Spot Secondary priced at $2.85

2025-10-24T10:41:05.000Z - 10 months ago

X4 Pharmaceuticals 45.87M share Spot Secondary priced at $2.85

X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering

Oct 24, 2025, 12:37 AM EDT - 10 months ago

X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering

X4 Pharmaceuticals announces common stock offering, no amount given

2025-10-23T20:05:36.000Z - 10 months ago

X4 Pharmaceuticals announces common stock offering, no amount given

X4 Pharmaceuticals Announces Proposed Underwritten Public Offering

Oct 23, 2025, 4:01 PM EDT - 10 months ago

X4 Pharmaceuticals Announces Proposed Underwritten Public Offering

X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation

Sep 17, 2025, 7:00 AM EDT - 1 year ago

X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation

X4 Pharmaceuticals Registration statement: Registration Filing

Sep 10, 2025, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals Registration statement: Registration Filing

X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement

Aug 13, 2025, 7:00 AM EDT - 1 year ago

X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement

X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership

Aug 12, 2025, 7:00 AM EDT - 1 year ago

X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership

X4 Pharmaceuticals Quarterly report: Q2 2025

Aug 8, 2025, 4:00 PM EDT - 1 year ago

X4 Pharmaceuticals Quarterly report: Q2 2025

X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)

Jun 16, 2025, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)

X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA

Jun 10, 2025, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress

May 14, 2025, 4:12 PM EDT - 1 year ago

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress

X4 Pharmaceuticals Earnings Call Transcript: Q1 2025

May 1, 2025, 8:30 AM EDT - 1 year ago

X4 Pharmaceuticals Earnings Call Transcript: Q1 2025

X4 Pharmaceuticals Quarterly report: Q1 2025

May 1, 2025, 8:30 AM EDT - 1 year ago

X4 Pharmaceuticals Quarterly report: Q1 2025

X4 Pharmaceuticals Earnings release: Q1 2025

May 1, 2025, 8:30 AM EDT - 1 year ago

X4 Pharmaceuticals Earnings release: Q1 2025

X4 Pharmaceuticals Slides: Q1 2025

May 1, 2025, 8:30 AM EDT - 1 year ago

X4 Pharmaceuticals Slides: Q1 2025

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 1, 2025, 6:01 AM EDT - 1 year ago

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

X4 Pharmaceuticals Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals Proxy statement: Proxy Filing

X4 Pharmaceuticals Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals Proxy statement: Proxy Filing

X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025

Apr 24, 2025, 8:03 AM EDT - 1 year ago

X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025

X4 Pharmaceuticals Announces Reverse Stock Split

Apr 24, 2025, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals Announces Reverse Stock Split

X4 Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 25, 2025, 8:30 AM EDT - 1 year ago

X4 Pharmaceuticals Earnings Call Transcript: Q4 2024

X4 Pharmaceuticals Annual report: Q4 2024

Mar 25, 2025, 8:30 AM EDT - 1 year ago

X4 Pharmaceuticals Annual report: Q4 2024

X4 Pharmaceuticals Earnings release: Q4 2024

Mar 25, 2025, 8:30 AM EDT - 1 year ago

X4 Pharmaceuticals Earnings release: Q4 2024

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 25, 2025, 6:01 AM EDT - 1 year ago

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Proxy statement: Proxy Filing

Mar 24, 2025, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals Proxy statement: Proxy Filing

X4 Pharmaceuticals Proxy statement: Proxy Filing

Mar 14, 2025, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals Proxy statement: Proxy Filing

X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025

Mar 11, 2025, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025

X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries

Feb 19, 2025, 7:35 AM EST - 1 year ago

X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries

X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia

Feb 6, 2025, 7:35 AM EST - 1 year ago

X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome

Jan 24, 2025, 7:36 AM EST - 1 year ago

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome

X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand

Jan 13, 2025, 7:35 AM EST - 1 year ago

X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand

X4 Pharmaceuticals Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 11:00 AM EST - 1 year ago

X4 Pharmaceuticals Transcript: Piper Sandler 36th Annual Healthcare Conference

X4 Pharmaceuticals Transcript: Stifel 2024 Healthcare Conference

Nov 18, 2024, 4:10 PM EST - 1 year ago

X4 Pharmaceuticals Transcript: Stifel 2024 Healthcare Conference

X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference

Nov 14, 2024, 8:00 AM EST - 1 year ago

X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference

X4 Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 13, 2024, 8:00 AM EST - 1 year ago

X4 Pharmaceuticals Earnings Call Transcript: Q3 2024

X4 Pharmaceuticals Quarterly report: Q3 2024

Nov 13, 2024, 8:00 AM EST - 1 year ago

X4 Pharmaceuticals Quarterly report: Q3 2024

X4 Pharmaceuticals Earnings release: Q3 2024

Nov 13, 2024, 8:00 AM EST - 1 year ago

X4 Pharmaceuticals Earnings release: Q3 2024

X4 Pharmaceuticals Slides: Q3 2024

Nov 13, 2024, 8:00 AM EST - 1 year ago

X4 Pharmaceuticals Slides: Q3 2024

X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 6:07 AM EST - 1 year ago

X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)

Nov 13, 2024, 6:01 AM EST - 1 year ago

X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)

X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024

Oct 24, 2024, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024

X4 Pharmaceuticals Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 17, 2024, 3:40 PM EDT - 2 years ago

X4 Pharmaceuticals Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

X4 Pharmaceuticals Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Sep 4, 2024, 2:35 PM EDT - 2 years ago

X4 Pharmaceuticals Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences

Aug 28, 2024, 8:00 AM EDT - 2 years ago

X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences

X4 Pharmaceuticals Earnings Call Transcript: Q2 2024

Aug 8, 2024, 8:30 AM EDT - 2 years ago

X4 Pharmaceuticals Earnings Call Transcript: Q2 2024

X4 Pharmaceuticals Quarterly report: Q2 2024

Aug 8, 2024, 8:30 AM EDT - 2 years ago

X4 Pharmaceuticals Quarterly report: Q2 2024

X4 Pharmaceuticals Earnings release: Q2 2024

Aug 8, 2024, 8:30 AM EDT - 2 years ago

X4 Pharmaceuticals Earnings release: Q2 2024

X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Aug 8, 2024, 6:01 AM EDT - 2 years ago

X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

X4 Pharmaceuticals Transcript: Study Update

Jun 27, 2024, 8:00 AM EDT - 2 years ago

X4 Pharmaceuticals Transcript: Study Update

X4 Pharmaceuticals Press release: Study Update

Jun 27, 2024, 8:00 AM EDT - 2 years ago

X4 Pharmaceuticals Press release: Study Update

X4 Pharmaceuticals Slides: Study Update

Jun 27, 2024, 8:00 AM EDT - 2 years ago

X4 Pharmaceuticals Slides: Study Update

X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial

Jun 27, 2024, 6:30 AM EDT - 2 years ago

X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial

X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia

May 29, 2024, 4:30 PM EDT - 2 years ago

X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia

X4 Pharmaceuticals Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 20, 2024, 2:00 PM EDT - 2 years ago

X4 Pharmaceuticals Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 13, 2024, 8:00 AM EDT - 2 years ago

X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility

May 9, 2024, 6:30 AM EDT - 2 years ago

X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility

X4 Pharmaceuticals Earnings Call Transcript: Q1 2024

May 7, 2024, 8:30 AM EDT - 2 years ago

X4 Pharmaceuticals Earnings Call Transcript: Q1 2024

X4 Pharmaceuticals Quarterly report: Q1 2024

May 7, 2024, 8:30 AM EDT - 2 years ago

X4 Pharmaceuticals Quarterly report: Q1 2024

X4 Pharmaceuticals Earnings release: Q1 2024

May 7, 2024, 8:30 AM EDT - 2 years ago

X4 Pharmaceuticals Earnings release: Q1 2024

X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

May 7, 2024, 6:01 AM EDT - 2 years ago

X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024

Apr 30, 2024, 8:00 AM EDT - 2 years ago

X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024

X4 Pharmaceuticals Transcript: FDA Announcement

Apr 29, 2024, 8:30 AM EDT - 2 years ago

X4 Pharmaceuticals Transcript: FDA Announcement

X4 Pharmaceuticals Press release: FDA Announcement

Apr 29, 2024, 8:30 AM EDT - 2 years ago

X4 Pharmaceuticals Press release: FDA Announcement

X4 Pharmaceuticals Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

X4 Pharmaceuticals Proxy statement: Proxy Filing

X4 Pharmaceuticals Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

X4 Pharmaceuticals Proxy statement: Proxy Filing

US FDA approves X4 Pharmaceuticals' drug for immunodeficiency disease

Apr 29, 2024, 6:37 AM EDT - 2 years ago

US FDA approves X4 Pharmaceuticals' drug for immunodeficiency disease

X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome

Apr 29, 2024, 6:30 AM EDT - 2 years ago

X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome

X4 Pharmaceuticals Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 8, 2024, 9:30 AM EDT - 2 years ago

X4 Pharmaceuticals Transcript: 23rd Annual Needham Virtual Healthcare Conference

X4 Pharmaceuticals Slides: 23rd Annual Needham Virtual Healthcare Conference

Apr 8, 2024, 9:30 AM EDT - 2 years ago

X4 Pharmaceuticals Slides: 23rd Annual Needham Virtual Healthcare Conference

X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences

Apr 1, 2024, 8:00 AM EDT - 2 years ago

X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences

X4 Pharmaceuticals Slides: Investor Presentation

Mar 28, 2024, 8:00 AM EDT - 2 years ago

X4 Pharmaceuticals Slides: Investor Presentation

X4 Pharmaceuticals Earnings Call Transcript: Q4 2023

Mar 21, 2024, 8:30 AM EDT - 2 years ago

X4 Pharmaceuticals Earnings Call Transcript: Q4 2023

X4 Pharmaceuticals Annual report: Q4 2023

Mar 21, 2024, 8:30 AM EDT - 2 years ago

X4 Pharmaceuticals Annual report: Q4 2023

X4 Pharmaceuticals Earnings release: Q4 2023

Mar 21, 2024, 8:30 AM EDT - 2 years ago

X4 Pharmaceuticals Earnings release: Q4 2023

X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

Mar 21, 2024, 6:01 AM EDT - 2 years ago

X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024

Mar 12, 2024, 8:00 AM EDT - 2 years ago

X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024

X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023

Dec 9, 2023, 12:00 PM EST - 2 years ago

X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023

X4 Pharmaceuticals Transcript: Piper Sandler 35th Annual Healthcare Conference

Nov 28, 2023, 1:00 PM EST - 2 years ago

X4 Pharmaceuticals Transcript: Piper Sandler 35th Annual Healthcare Conference

X4 Pharmaceuticals Slides: Investor Presentation

Nov 27, 2023, 5:00 PM EST - 2 years ago

X4 Pharmaceuticals Slides: Investor Presentation

X4 Pharmaceuticals to Participate in Upcoming November Investor Conferences

Nov 10, 2023, 8:00 AM EST - 3 years ago

X4 Pharmaceuticals to Participate in Upcoming November Investor Conferences

starkist
starkist Aug. 14 at 11:44 AM
$XFOR something is going on here ...whatever it is ...i haven't a clue.. been sitting on this for too many years.. and only once in very blue moon do i come here and take a peak.. but i like this hint of northern movement.
1 · Reply
Pope25
Pope25 Aug. 10 at 8:05 PM
$XFOR ok boys, time to load up
0 · Reply
TwongStocks
TwongStocks Aug. 6 at 8:33 PM
$XFOR 10-Q filed https://www.sec.gov/ix?doc=/Archives/edgar/data/1501697/000150169726000068/xfor-20260630.htm • 99,146,743 shares outstanding as of July 31 • $2.4M in product revenue. $6.4M in license revenue from Norgine, which included $5.5M in milestone payments. Total revenue $8.8M. • Net loss per share ($0.13)
2 · Reply
Jeff226
Jeff226 Aug. 5 at 2:56 PM
$XFOR
0 · Reply
StockScanners
StockScanners Jul. 11 at 10:37 PM
$XFOR keep watch if this holds above 4.24
0 · Reply
IN0V8
IN0V8 Jul. 10 at 3:24 PM
$XFOR Buy Wells Fargo initiates coverage with overweight rating Wells Fargo initiates target price $11
0 · Reply
dl42
dl42 Jul. 10 at 11:55 AM
$XFOR here some positive news
0 · Reply
Jeff226
Jeff226 Jun. 30 at 6:17 PM
$XFOR
0 · Reply
Pope25
Pope25 Jun. 26 at 2:49 AM
$XFOR might go visit the low 3’s again
0 · Reply
Skusek
Skusek May. 31 at 11:29 PM
$XFOR Still heavily unprofitable: X4 reported a 2025 net loss of about $79 million and continues to post significant quarterly losses despite restructuring efforts.•.
1 · Reply
TwongStocks
TwongStocks May. 22 at 11:06 PM
$XFOR On preliminary list of stocks being added to Russell index https://www.lseg.com/content/dam/ftse-russell/en_us/documents/other/ru3000-additions-20260522.pdf Russell index changes will be finalized at market close on June 26
0 · Reply
I_Hate_Stock_Twits
I_Hate_Stock_Twits May. 15 at 6:42 AM
$XFOR the cart is saying not so fast regarding being range bound. Wait.
1 · Reply
Pope25
Pope25 May. 4 at 7:11 PM
$XFOR rangebound until ph3 is enrolled. see you in september
0 · Reply
Jeff226
Jeff226 Apr. 29 at 1:14 PM
$XFOR
0 · Reply
DARKP00L
DARKP00L Apr. 29 at 11:32 AM
$XFOR 07:14 on Apr. 29 2026 X4 Pharma Says EC Grants Marketing Authorization For XOLREMDI Capsules For Treatment Of Patients With WHIM Syndrome In EU #tradeideas
0 · Reply
TwongStocks
TwongStocks Apr. 29 at 11:01 AM
$XFOR X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union https://investors.x4pharma.com/news-releases/news-release-details/x4-pharmaceuticals-announces-european-commission-approval
0 · Reply
I_Hate_Stock_Twits
I_Hate_Stock_Twits Apr. 24 at 3:30 PM
$XFOR They did sell the prv and that clown woke DEI woman now ex CEO few off to enjoy their Geneva office overseas to be sure.
0 · Reply
Merlintrader
Merlintrader Apr. 20 at 9:35 PM
$XFOR X4 Pharmaceuticals ( $XFOR): post-approval reset, new management, and a binary-but-cleaner road toward the 4WARD readout https://merlintrader.com/x4-pharmaceuticals-april2026-deepdive/
0 · Reply
smk8706
smk8706 Apr. 19 at 5:26 PM
$XFOR hedge fund buying increased by 10 million... good/bad? Whats everyones first thought when they read this?
0 · Reply
Stephanovich7654568
Stephanovich7654568 Apr. 7 at 3:13 PM
$RCKT $XFOR . XFOR is an eternal loser. Look at how many stock split events they went trought. RCKT has a chance.
0 · Reply
Zkoko_Bio
Zkoko_Bio Apr. 7 at 11:09 AM
$RCKT don't expect much from PRVs. Remember for example when $XFOR sold its PRV for nearly as much as its MC back then? Stock price just acted as if nothing happened...
1 · Reply
focafoca99
focafoca99 Apr. 1 at 9:51 PM
$XFOR reported inducement grants covering 32,000 shares for new employees.
0 · Reply